Gyre Therapeutics, Inc. Share-based Payment Arrangement, Plan Modification, Incremental Cost
Gyre Therapeutics, Inc. (GYRE) reported Share-based Payment Arrangement, Plan Modification, Incremental Cost of $106.00 thousand for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost · last filed 2013-11-06
- Gyre Therapeutics, Inc. share-based payment arrangement, plan modification, incremental cost for the quarter ending 2013-09-30 was $106.00K.
- Gyre Therapeutics, Inc. share-based payment arrangement, plan modification, incremental cost for the quarter ending 2013-06-30 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. share-based payment arrangement, plan modification, incremental cost for the quarter ending 2013-03-31 was $467.00K.
- Gyre Therapeutics, Inc. share-based payment arrangement, plan modification, incremental cost for the quarter ending 2012-09-30 was $0.00.
| Period end | Share-based Payment Arrangement, Plan Modification, Incremental Cost 3 month | Share-based Payment Arrangement, Plan Modification, Incremental Cost 6 month | Share-based Payment Arrangement, Plan Modification, Incremental Cost 9 month |
|---|---|---|---|
| 2013-09-30 | $106.00K 10-Q · filed 2013-11-06 | $106.00K derived: sum of 2 quarters · filed 2013-11-06 | $573.00K 10-Q · filed 2013-11-06 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $467.00K 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $467.00K 10-Q · filed 2013-05-08 | ||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $1.30M derived: sum of 2 quarters · filed 2012-11-08 | $1.30M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $1.30M 10-Q · filed 2012-08-09 | $1.30M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |